Straits Times Index
3,111.65 +18.85 (+0.61%) Nikkei
26,491.97 +320.72 (+1.23%) Hang Seng
21,719.06 +445.19 (+2.09%) FTSE 100
7,208.81 +188.36 (+2.68%) BTC-USD
21,434.26 +159.44 (+0.75%) CMC Crypto 200
462.12 +8.22 (+1.81%)
Precision BioSciences, Inc. (DTIL)
After hours:
| Previous close | 1.4600 |
| Open | 1.4900 |
| Bid | 1.4300 x 900 |
| Ask | 1.4500 x 2900 |
| Day's range | 1.4350 - 1.5900 |
| 52-week range | 1.1100 - 14.3800 |
| Volume | |
| Avg. volume | 1,859,937 |
| Market cap | 90.156M |
| Beta (5Y monthly) | 1.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6700 |
| Earnings date | 10 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.33 |
- Zacks
Precision BioSciences' (DTIL) Stock Up This Week: Here's Why
Shares of Precision BioSciences (DTIL) are up as the company inks a gene-editing deal with Novartis to develop a potentially curative treatment for disorders like sickle cell disease.
- Business Wire
Precision BioSciences Announces $50 Million Offering of Common Stock
DURHAM, N.C., June 21, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately $50.0 million. The offering is expected to close on or about June 24, 2022, subject to customary closing conditions. All
- Business Wire
Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease
DURHAM, N.C., June 21, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma AG (the "Agreement"). As part of the Agreement, Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a ther
